2026-05-22T05:28:06Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/144832024-11-29T10:02:29Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16977

00925njm 22002777a 4500 dc Álvarez, Beatriz author Navarrete-Muñoz, María A author Briz, Veronica author Olmedillas-López, Susana author Nistal, Sara author Cabello, Alfonso author Prieto, Laura author Górgolas, Miguel author García-Arranz, Mariano author Benito, José Miguel author Rallón, Norma author 2022-03-24 The role of HCV on the HIV reservoir is controversial since the reduction on HIV-DNA levels after HCV eradication with IFNα/RBV treatment seems to be the result of drugs instead of HCV clearance. We assessed whether HCV eradication can decrease HIV-DNA content in HIV/HCV-coinfected patients treated with direct-acting antivirals, DAAs (IFNα/RBV-free regimens). Cell-associated HIV-DNA was measured by ddPCR in 25 HIV-monoinfected and 25 HIV/HCV-coinfected patients. There were no differences in HIV-DNA levels between groups neither at baseline nor at 12 weeks after DAAs treatment completion. Our results indicate that HCV does not appear to influence the HIV reservoir size and suggest the lack of an anti-HIV action for DAAs. Sci Rep. 2022 Mar 24;12(1):5095. 10.1038/s41598-022-08871-0 2045-2322 Scientific Reports 35332180 http://hdl.handle.net/20.500.12105/14483 HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy